LAVA Therapeutics NV (LVTX)
2.26
-0.14
(-5.83%)
USD |
NASDAQ |
May 31, 16:00
2.28
+0.02
(+0.88%)
After-Hours: 20:00
LAVA Therapeutics Net Income (Quarterly): -0.553M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.553M |
| December 31, 2023 | -6.498M |
| September 30, 2023 | -8.836M |
| June 30, 2023 | -12.70M |
| March 31, 2023 | -13.94M |
| December 31, 2022 | -14.92M |
| September 30, 2022 | 0.936M |
| June 30, 2022 | -8.106M |
| March 31, 2022 | -9.822M |
| Date | Value |
|---|---|
| December 31, 2021 | -8.219M |
| September 30, 2021 | -6.933M |
| June 30, 2021 | -8.037M |
| March 31, 2021 | -19.74M |
| December 31, 2020 | -3.591M |
| September 30, 2020 | -3.945M |
| June 30, 2020 | -3.902M |
| March 31, 2020 | -4.057M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-19.74M
Minimum
Mar 2021
0.936M
Maximum
Sep 2022
-7.815M
Average
-8.037M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
| uniQure NV | -65.62M |
| ProQR Therapeutics NV | -8.318M |
| Merus NV | -34.46M |
| argenx SE | -61.60M |
| Pharming Group | -12.45M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 6.992M |
| Total Expenses (Quarterly) | 8.944M |
| EPS Diluted (Quarterly) | -0.02 |
| Enterprise Value | -29.86M |
| Profit Margin (Quarterly) | -7.91% |
| Earnings Yield | -46.90% |
| Normalized Earnings Yield | -47.12 |